Tonix Pharmaceuticals

Update in progress

TNXP (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company focused on therapies for CNS disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. It markets TONMYA for fibromyalgia and Zembrace SymTouch and Tosymra for acute migraine in adults. Its pipeline includes TNX-102 SL, TNX-1300, TNX-1500, TNX-4800, TNX-2900, TNX-801, TNX-4200, TNX-4900, TNX-1700, and TNX-1800/1850. Founded 2007, based in Berkeley Heights, NJ.

Company score

Sentiment: 0.55; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.64; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.26; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.25; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.40; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive